Skip to content
ES
MARKETS / NASDAQ / MEDP
NASDAQ · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH · LARGE CAP

Medpace Holdings, Inc. MEDP

11 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.5B
▲ 20.0% YoY
$451.1M
▲ 11.6% YoY
$681.9M
▲ 19.2% YoY
In brief

What this company does

Medpace Holdings, Inc. provides outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. It generates its revenues by providing a full suite of services supporting the entire clinical development process from Phase I to Phase IV across a wide range of therapeutic areas. Its team of clinical trial managers leads all aspects of study execution and drives accountability across the functional team members. Its material trademarks include Medpace and ClinTrak. As of December 31, 2025 it had approximately 6,200 employees located across 46 countries. Its Central Laboratory operates in four locations, including Cincinnati, Ohio; Leuven, Belgium; Shanghai, China; and Singapore.

Written from the business description in Medpace Holdings, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 10 February 2026. Every sentence was checked against that document before publication.

Growth
USD 2.5B
Revenue, FY2025 · full 11-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.5 · Net income 0.5
1B2B201520172019202120232025
Compound annual growth
+20.1%
+22.3%
+21.6%
+22.5%
+25.4%
+28.0%
+31.8%
+1.4%
+59.9%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +22.3% a year over five years — but profit grew faster: net income at +25.4%, earnings per share at +31.8%.

The share count fell from 0.04B to 0.03B — the buyback concentrates the same profit into fewer slices.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
18 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 21.1% · Net 17.8%
10%20%-1%-2%201520172019202120232025
ROE
FY2025 · ROE 70.2%
20%40%60%201520172019202120232025
Gross margin30.1%
Operating margin21.1%
Net margin17.8%
Return on assets22.1%
EBITDAUSD 562.1M

Each USD of equity produced 70 cents of profit this year.

Cash & shareholders
USD 860.4M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 681.9
250.0M500.0M201520172019202120232025
Net buybacks $M Dividends $M
FY2025 · Dividends — · Net buybacks 860.4
400M800M-80M-160M201520172019202120232025
Dividends paid—
Net buybacksUSD 860.4M
Share of profit190.7%
Consecutive raises—

USD 860.4M in buybacks — 191% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 2.0B
EquityUSD 459.1M
CashUSD 497.0M
Current ratio0.74×

Equity funds 23% of total assets.

The 11-year record
11 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 20252024202320222021202020192018201720162015
Revenue $B2.52.11.91.51.10.90.90.70.40.40.4
Operating income $B0.50.40.30.30.20.20.10.10.10.10.0
EBITDA $B0.60.50.40.30.20.20.10.10.10.10.0
Income tax $B0.10.10.10.00.00.00.00.00.00.00.0
Net income $B0.50.40.30.20.20.10.10.10.00.0−0.0
Free cash flow $B0.70.60.40.40.20.20.20.10.10.10.1
EPS, diluted $15.2812.638.887.284.813.842.671.970.980.37−0.28
Dividend / sh $···········
Payout %···········
ROE %70.258.459.836.620.719.015.213.27.02.6−2.1
Shares out B0.030.030.030.030.040.040.040.040.040.040.03

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 45 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 40 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Commercial Physical & Biological Research
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image